New positive topline findings have been announced by InnoCare Pharma following a registrational phase 3 trial assessing the investigational TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis, with the drug attaining its primary efficacy endpoint along with several secondary endpoints.1
Key Takeaways:
- Soficitinib met the primary endpoint in a phase 3 trial of patients with moderate-to-severe atopic dermatitis and also achieved multiple secondary efficacy endpoints.
- The investigational oral TYK2 inhibitor maintained a favorable safety profile, with no new safety signals reported compared with previous clinical studies.
- Beyond atopic dermatitis, soficitinib is being evaluated for several inflammatory skin diseases, including psoriasis, vitiligo, prurigo nodularis, and chronic spontaneous urticaria, highlighting the expanding potential of TYK2-targeted therapies in dermatology.
Soficitinib is an investigational oral inhibitor of tyrosine kinase 2 (TYK2), a signaling protein involved in the JAK-STAT pathway known to contribute to immune-mediated inflammation.1,2 By selectively targeting TYK2, the therapy is being developed to modulate inflammatory pathways implicated in a range of autoimmune disorders. This randomized, multi-center, double-blind, placebo-controlled analysis was designed to look into the efficacy, safety, and tolerability of oral soficitinib in adults with moderate-to-severe disease.
“We are happy to see that soficitinib has met the primary endpoint in the Phase III studies in atopic dermatitis with excellent clinical results,” Jasmine Cui, PharmD, the co-founder, chairwoman and CEO of InnoCare, said in a statement.1 “[Atopic dermatitis] is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, eczema and substantial impairment in patients' quality of life.”
What Did the Phase 3 Trial Show for Soficitinib in Atopic Dermatitis?
In the company’s release, they pointed to treatment with soficitinib as having resulted in statistically significant and clinically meaningful improvements versus placebo, while demonstrating consistent benefits across several additional efficacy measures. The trial investigators also noted the therapy’s maintenance of a favorable safety profile throughout their research.
The safety findings were shown to be consistent with those observed in earlier clinical research, and the team did not identify any previously unrecognized safety concerns during the phase 3 program. Additional efficacy and safety data are expected to be presented at future scientific meetings and published in peer-reviewed journals.
What Other Skin Diseases Is Soficitinib Being Studied For?
Outside of treating atopic dermatitis, InnoCare is investigating soficitinib across several dermatologic conditions. These conditions include vitiligo, psoriasis, prurigo nodularis, and chronic spontaneous urticaria (CSU). The company's broader development strategy mentioned in their release reflects growing interest in TYK2 inhibition as a therapeutic approach.
“We will continue to complete the Phase III study, and plan to advance the regulatory filing to bring better treatment option to patients with atopic dermatitis and other autoimmune diseases,” Cui said in her statement.1
The announcement highlights the skin disease’s substantial global health burden, with the World Health Organization's Global Burden of Disease study suggesting approximately 230 million people worldwide are still impacted by the condition.
References
Xu J, Zhang L, Liang Y, et al. Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. Published online January 14, 2026. Accessed July 15, 2026. doi:10.1001/jamadermatol.2025.5295.
